"With Today’s Decision, the Commission Contributes to Keeping Drugs Affordable, Preserving Choice of Treatment and Fostering Innovation, to the Benefit of EU Patients and National Healthcare Systems," She Added.Brussels, Oct 31 (Reuters) - The European Commission Has Fined Teva Teva.ta, the World's Largest Generic Drugmaker, 462.6 Million Euros ($503 Million) for Abusing Its Dominant Position to Delay Competition to Its Blockbuster Multiple Sclerosis Medicine Copaxone, Confirming a Reuters Exclusive.
布魯塞爾，10月31日（路透社）— 歐盟委員會已對Teva處以罰款 Teva.ta，全球最大的仿製藥製造商，46260萬歐元（合5.03億美元），原因是濫用其主導地位，推遲了與其轟動一時的多發性硬化症藥物Copaxone的競爭， 確認路透社獨家報道。
The European Commission Said on Thursday It Had Found That Teva Artificially Extended the Patent Protection of Copaxone and Systematically Spread Misleading Information About a Rival Product.
歐盟委員會週四表示，它發現Teva人爲地延長了Copaxone的專利保護，並系統地散佈了有關競爭對手產品的誤導性信息。
"Today's Decision to Impose an Antitrust Fine on Teva for Disparagement and Misuse of the Patent System Reaffirms the
“今天以貶低和濫用專利制度爲由對Teva處以反壟斷罰款的決定重申了這一點
Commission's Commitment to Competition Enforcement in the Pharmaceutical Sector," Said EU Antitrust Chief Margrethe Vestager.
歐盟委員會對製藥行業競爭執法的承諾，” 歐盟反壟斷負責人瑪格麗特·維斯塔格說。
"With Today’s Decision, the Commission Contributes to Keeping Drugs Affordable, Preserving Choice of Treatment and Fostering Innovation, to the Benefit of EU Patients and National Healthcare Systems," She Added.
她補充說：「通過今天的決定，歐盟委員會爲保持藥品價格合理、保留治療選擇和促進創新做出了貢獻，使歐盟患者和國家醫療保健系統受益。」
($1 = 0.9197 Euros)
($1 = 0.9197 歐元)
(Reporting by Sudip Kar-Gupta;
Editing by Tassilo Hummel/Foo Yun Chee)
（Sudip Kar-Gupta 報道；
由 Tassilo Hummel/Foo Yun Chee 編輯）
